HeraMED Limited (HMD.AX)
HeraMED Limited operates in the Medical - Devices industry of the Healthcare sector, headquartered in Hawthorn East, VIC, AU. The stock last traded at $0.04, up 0.00% on the session, giving a market capitalisation of $44.0M. Its beta of 0.05 implies it has historically moved less than the broad market.
HeraMED Limited and its associated entities are dedicated to the design, production, and sale of at-home fetal heart rate monitors and comprehensive pregnancy monitoring systems. These solutions are offered to consumers throughout Australia, Europe, and Israel. Key products include HeraBEAT, a device enabling expectant mothers to personally track their baby's heartbeat, and HeraCARE, a sophisticated digital platform facilitating the creation and deployment of health solutions for effective maternity care management. The company is also at the forefront of developing EchoBEAT, envisioned as the subsequent evolution of its domestic pregnancy monitoring tools, alongside Orion, an artificial intelligence-driven system engineered for profound pregnancy monitoring analysis. A strategic partnership with Mayo Clinic supports the ongoing advancement of the HeraCARE pregnancy management platform. Established in 2011, HeraMED Limited operates from its main office in Netanya, Israel.
HeraMED Limited is most often compared with the following Healthcare names: